Clinical trial
The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder
NCT00044187 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2001
- Completion date
- September 30, 2003
- Enrollment
- 130
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.